GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (FRA:LUP) » Definitions » Short-Term Debt

Luye Pharma Group (FRA:LUP) Short-Term Debt : €992.3 Mil (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Short-Term Debt?

Luye Pharma Group's Short-Term Debt for the quarter that ended in Dec. 2024 was €992.3 Mil.

Luye Pharma Group's quarterly Short-Term Debt increased from Dec. 2023 (€664.9 Mil) to Jun. 2024 (€851.7 Mil) and increased from Jun. 2024 (€851.7 Mil) to Dec. 2024 (€992.3 Mil).

Luye Pharma Group's annual Short-Term Debt declined from Dec. 2022 (€924.1 Mil) to Dec. 2023 (€664.9 Mil) but then increased from Dec. 2023 (€664.9 Mil) to Dec. 2024 (€992.3 Mil).

Luye Pharma Group Short-Term Debt Historical Data

The historical data trend for Luye Pharma Group's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Short-Term Debt Chart

Luye Pharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 707.68 728.15 924.07 664.90 992.33

Luye Pharma Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 924.07 998.48 664.90 851.70 992.33

Luye Pharma Group Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Luye Pharma Group Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (FRA:LUP) » Definitions » Short-Term Debt
Comparable Companies
HKSE:00460 HKSE:01681 HKSE:02005 HKSE:03613 HKSE:01349 HKSE:00570 HKSE:02877 HKSE:02561 HKSE:06185 HKSE:06896 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
LYPHF:USA 02186:Hong Kong
Address
Hongqiao Road 1438, 22/F, Gubei International Fortune Center II, Changning District, Shanghai, CHN, 264003
Website
https://www.luye.cn
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs, Central nervous system drugs and others. It derives maximum revenue from the sale of Oncology drugs.

Luye Pharma Group Headlines

No Headlines